LG
LGND
Market ClosedLigand Pharmaceuticals Incorporated
US
47 employees
CEO: Todd C. Davis
Founded: 1992
$280.87
+$0.00(+NaN%)
Market Cap
5.63B
Beta
0.98
52W Range
N/A
Dividend Yield
0.00%
Comprehensive Valuation
In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Based on PERT weighted analysis (confidence: high), the fair value is $623.62, implying 123.1% upside from current levels. The stock appears significantly undervalued. Financial health scores indicate strong fundamentals (4.2/5). Monte Carlo analysis shows high downside risk (100% of scenarios below current price). Overall, this suggests a compelling buying opportunity at current prices.
Enhanced Football Field Analysis
Loading comprehensive valuation data...
Fetching multi-methodology valuation ranges...
Explore LGND
LGND in the Healthcare
Mid Cap